SK Bioscience Co Ltd (302440) — Capital Reinvestment Ratio
Latest as of September 2025:
3.44x
SK Bioscience Co Ltd (302440) has a Capital Reinvestment Ratio of 3.44x as of September 2025, meaning it reinvests 3% of its operating cash flow (₩20.65 Billion) in capital expenditures (₩70.94 Billion). See SK Bioscience Co Ltd (302440) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.44x
Capex / Operating Cash Flow
Operating Cash Flow
₩20.65 Billion
KRW
Capital Expenditures
₩70.94 Billion
KRW
Data as of
Sep 2025
Most recent filing
SK Bioscience Co Ltd Capital Reinvestment Ratio (2018–2023)
This chart tracks SK Bioscience Co Ltd's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for SK Bioscience Co Ltd (2018–2023)
Year-by-year Capital Reinvestment Ratio for SK Bioscience Co Ltd from 2018 to 2023. For live market cap and broader valuation context, see SK Bioscience Co Ltd (302440) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.71x | ₩29.35 Billion | ₩50.30 Billion | ▲ +2043.3% |
| 2021 | 0.08x | ₩536.59 Billion | ₩42.91 Billion | ▼ -3.2% |
| 2020 | 0.08x | ₩120.22 Billion | ₩9.93 Billion | ▼ -92.5% |
| 2019 | 1.10x | ₩21.82 Billion | ₩23.97 Billion | ▲ +159.4% |
| 2018 | 0.42x | ₩14.90 Billion | ₩6.31 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow